Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 93, Issue , 2015, Pages 149-164

  Bento, D ^a,b   Staats, H F ^c   Goncalves T ^a,d   Borges, O ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Alginate; Anthrax protective antigen; Chitosan; Compound 48 80; Mast cell activator; Mucosal immunity; Nanoparticles; Nasal vaccination

Indexed keywords

CHITOSAN NANOPARTICLE; NEUTRALIZING ANTIBODY; VACCINE; 4 METHOXY N METHYLPHENETHYLAMINE; ALGINIC ACID; ANTHRAX TOXIN; ANTHRAX VACCINE; BACTERIAL ANTIGEN; BACTERIAL TOXIN; BACTERIUM ANTIBODY; BIOLOGICAL MARKER; CHITOSAN; DRUG CARRIER; GLUCURONIC ACID; HEXURONIC ACID; IMMUNOLOGICAL ADJUVANT; NANOPARTICLE;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; HYPOTHESIS; IMMUNE RESPONSE; IMMUNIZATION; INTERNALIZATION; MAST CELL; MICROENVIRONMENT; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NOSE CAVITY; ANIMAL; ANTHRAX; BLOOD; C57BL MOUSE; CELL LINE RAW 264.7; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; FEMALE; HELPER CELL; HUMAN; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; MICROBIOLOGY; NANOMEDICINE; NOSE MUCOSA; PARTICLE SIZE; PHARMACEUTICS; PROCEDURES; SURFACE PROPERTY; TIME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ALGINATES; ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; BIOMARKERS; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; FEMALE; GLUCURONIC ACID; HEXURONIC ACIDS; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION; MAST CELLS; MICE; MICE, INBRED C57BL; NANOMEDICINE; NANOPARTICLES; NASAL MUCOSA; P-METHOXY-N-METHYLPHENETHYLAMINE; PARTICLE SIZE; RAW 264.7 CELLS; SURFACE PROPERTIES; T-LYMPHOCYTES, HELPER-INDUCER; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS;

EID: 84927513193     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2015.03.024     Document Type: Article

References (69)

1. O. Borges, F. Lebre, D. Bento, G. Borchard, and H.E. Junginger Mucosal vaccines: recent progress in understanding the natural barriers Pharm. Res. 27 2010 211 223
2. S.N. Abraham, and A.L. St. John Mast cell-orchestrated immunity to pathogens Nat. Rev. Immunol. 10 2010 440 452
3. M. Metz, and M. Maurer Mast cells-key effector cells in immune responses Trends Immunol. 28 2007 234 241
4. J.S. Marshall Mast-cell responses to pathogens Nat. Rev. Immunol. 4 2004 787 799
5. J.B. McLachlan, C.P. Shelburne, J.P. Hart, S.V. Pizzo, R. Goyal, R. Brooking-Dixon, H.F. Staats, and S.N. Abraham Mast cell activators: a new class of highly effective vaccine adjuvants Nat. Med. 14 2008 536 541
6. H.F. Staats, J.R. Fielhauer, A.L. Thompson, A.A. Tripp, A.E. Sobel, M. Maddaloni, S.N. Abraham, and D.W. Pascual Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits PLoS ONE 6 2011 e16532
7. A.L. McGowen, L.P. Hale, C.P. Shelburne, S.N. Abraham, and H.F. Staats The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen Vaccine 27 2009 3544 3552
8. S.H. Wang, S.M. Kirwan, S.N. Abraham, H.F. Staats, and A.J. Hickey Stable dry powder formulation for nasal delivery of anthrax vaccine J. Pharm. Sci. 101 2012 31 47
9. H. Kayamuro, Y. Yoshioka, Y. Abe, S. Arita, K. Katayama, T. Nomura, T. Yoshikawa, R. Kubota-Koketsu, K. Ikuta, S. Okamoto, Y. Mori, J. Kunisawa, H. Kiyono, N. Itoh, K. Nagano, H. Kamada, Y. Tsutsumi, and S. Tsunoda Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus J. Virol. 84 2010 12703 12712
10. Y. Fang, L. Larsson, J. Mattsson, N. Lycke, and Z. Xiang Mast cells contribute to the mucosal adjuvant effect of CTA1-DD after IgG-complex formation J. Immunol. 185 2010 2935 2941
11. V. Heib, M. Becker, T. Warger, G. Rechtsteiner, C. Tertilt, M. Klein, T. Bopp, C. Taube, H. Schild, E. Schmitt, and M. Stassen Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice Blood 110 2007 946 953
12. A.S. McKee, M.W. Munks, M.K. MacLeod, C.J. Fleenor, N. Van Rooijen, J.W. Kappler, and P. Marrack Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity J. Immunol. 183 2009 4403 4414
13. N. Yoshino, M. Endo, H. Kanno, N. Matsukawa, R. Tsutsumi, R. Takeshita, and S. Sato Polymyxins as novel and safe mucosal adjuvants to induce humoral immune responses in mice PLoS ONE 8 2013 e61643
14. D.M. Smith, J.K. Simon, and J.R. Baker Jr. Applications of nanotechnology for immunology Nat. Rev. Immunol. 13 2013 592 605
15. M.L. De Temmerman, J. Rejman, J. Demeester, D.J. Irvine, B. Gander, and S.C. De Smedt Particulate vaccines: on the quest for optimal delivery and immune response Drug Discov. Today 16 2011 569 582
16. P. Sahdev, L.J. Ochyl, and J.J. Moon Biomaterials for nanoparticle vaccine delivery systems Pharm. Res. 2014
17. L. Zhao, A. Seth, N. Wibowo, C.X. Zhao, N. Mitter, C. Yu, and A.P. Middelberg Nanoparticle vaccines Vaccine 2013
18. M. Vajdy, I. Srivastava, J. Polo, J. Donnelly, D. O'Hagan, and M. Singh Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines Immunol. Cell Biol. 82 2004 617 627
19. H.C. Arca, M. Gunbeyaz, and S. Senel Chitosan-based systems for the delivery of vaccine antigens Expert Rev. Vaccines 8 2009 937 953
20. I. Jabbal-Gill, P. Watts, and A. Smith Chitosan-based delivery systems for mucosal vaccines Expert Opin. Drug Deliv. 9 2012 1051 1067
21. Y. Wu, S. Wu, L. Hou, W. Wei, M. Zhou, Z. Su, J. Wu, W. Chen, and G. Ma Novel thermal-sensitive hydrogel enhances both humoral and cell-mediated immune responses by intranasal vaccine delivery Eur. J. Pharm. Biopharm. 81 2012 486 497
22. K.A. Woodrow, K.M. Bennett, and D.D. Lo Mucosal vaccine design and delivery Annu. Rev. Biomed. Eng. 14 2012 17 46
23. V.E. Schijns, and E.C. Lavelle Trends in vaccine adjuvants Expert Rev. Vaccines 10 2011 539 550
24. G. Mutwiri, V. Gerdts, S. van Drunen Littel-van den Hurk, G. Auray, N. Eng, S. Garlapati, L.A. Babiuk, and A. Potter Combination adjuvants: the next generation of adjuvants? Expert Rev. Vaccines 10 2011 95 107
25. O. Borges, M. Silva, A. de Sousa, G. Borchard, H.E. Junginger, and A. Cordeiro-da-Silva Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen Int. Immunopharmacol. 8 2008 1773 1780
26. E. Mata, M. Igartua, M.E. Patarroyo, J.L. Pedraz, and R.M. Hernandez Enhancing immunogenicity to PLGA microparticulate systems by incorporation of alginate and RGD-modified alginate Eur. J. Pharm. Sci.: Off. J. Eur. Feder. Pharm. Sci. 44 2011 32 40
27. D. Yang, and K.S. Jones Effect of alginate on innate immune activation of macrophages J. Biomed. Mater. Res. A 90 2009 411 418
28. A. Bender, M. Sapp, G. Schuler, R.M. Steinman, and N. Bhardwaj Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood J. Immunol. Methods 196 1996 121 135
29. M. Rajaonarivony, C. Vauthier, G. Couarraze, F. Puisieux, and P. Couvreur Development of a new drug carrier made from alginate J. Pharm. Sci. 82 1993 912 917
30. D. Bento, G. Borchard, T. Goncalves, and O. Borges Validation of a new 96-well plate spectrophotometric method for the quantification of compound 48/80 associated with particles AAPS PharmSciTech 14 2013 649 655
31. O. Borges, A. Cordeiro-da-Silva, S.G. Romeijn, M. Amidi, A. de Sousa, G. Borchard, and H.E. Junginger Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination J. Control. Release: Off. J. Control. Release Soc. 114 2006 348 358
32. J. Lee, and K.T. Lim Inhibitory effect of phytoglycoprotein (24 kDa) on allergy-related factors in compound 48/80-induced mast cells in vivo and in vitro Int. Immunopharmacol. 10 2010 591 599
33. H.F. Staats, S.M. Kirwan, C.P. Shelburne, S.N. Abraham, G.Y. Leung, and D.Y. Chen A mast cell degranulation screening assay for the identification of novel mast cell activating agents MedChemComm 4 2013 88 94
34. B.S. Schaffer, M.H. Grayson, J.M. Wortham, C.B. Kubicek, A.T. McCleish, S.I. Prajapati, L.D. Nelon, M.M. Brady, I. Jung, T. Hosoyama, L.M. Sarro, M.A. Hanes, B.P. Rubin, J.E. Michalek, C.B. Clifford, A.J. Infante, and C. Keller Immune competency of a hairless mouse strain for improved preclinical studies in genetically engineered mice Mol. Cancer Ther. 9 2010 2354 2364
35. N. Hagenaars, M. Mania, P. de Jong, I. Que, R. Nieuwland, B. Slutter, H. Glansbeek, J. Heldens, H. van den Bosch, C. Lowik, E. Kaijzel, E. Mastrobattista, and W. Jiskoot Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine J. Control. Release: Off. J. Control. Release Soc. 144 2010 17 24
36. H.F. Staats, S.M. Alam, R.M. Scearce, S.M. Kirwan, J.X. Zhang, W.M. Gwinn, and B.F. Haynes In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity Infect. Immun. 75 2007 5443 5452
37. C. Foged, B. Brodin, S. Frokjaer, and A. Sundblad Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model Int. J. Pharm. 298 2005 315 322
38. E. Montomoli, S. Piccirella, B. Khadang, E. Mennitto, R. Camerini, and A. De Rosa Current adjuvants and new perspectives in vaccine formulation Expert Rev. Vaccines 10 2011 1053 1061
39. D.S. Stewart-Tull Harmful and beneficial activities of immunological adjuvants D. O'Hagan, Vaccine Adjuvants 2000 Springer New York 29 48
40. S. Lanone, F. Rogerieux, J. Geys, A. Dupont, E. Maillot-Marechal, J. Boczkowski, G. Lacroix, and P. Hoet Comparative toxicity of 24 manufactured nanoparticles in human alveolar epithelial and macrophage cell lines Part. Fibre Toxicol. 6 2009 14
41. M. Davoren, E. Herzog, A. Casey, B. Cottineau, G. Chambers, H.J. Byrne, and F.M. Lyng In vitro toxicity evaluation of single walled carbon nanotubes on human A549 lung cells Toxicol. In Vitro 21 2007 438 448 (an international journal published in association with BIBRA)
42. B. Mastelic, S. Ahmed, W.M. Egan, G. Del Giudice, H. Golding, I. Gust, P. Neels, S.G. Reed, R.L. Sheets, C.A. Siegrist, and P.H. Lambert Mode of action of adjuvants: implications for vaccine safety and design Biologicals: J. Int. Assoc. Biol. Stand. 38 2010 594 601
43. T. Marichal, K. Ohata, D. Bedoret, C. Mesnil, C. Sabatel, K. Kobiyama, P. Lekeux, C. Coban, S. Akira, K.J. Ishii, F. Bureau, and C.J. Desmet DNA released from dying host cells mediates aluminum adjuvant activity Nat. Med. 17 2011 996 1002
44. L.S. Jacobson, H. Lima Jr., M.F. Goldberg, V. Gocheva, V. Tsiperson, F.S. Sutterwala, J.A. Joyce, B.V. Gapp, V.A. Blomen, K. Chandran, T.R. Brummelkamp, F. Diaz-Griffero, and J. Brojatsch Cathepsin-mediated necrosis controls the adaptive immune response by Th2 (T helper type 2)-associated adjuvants J. Biol. Chem. 288 2013 7481 7491
45. V. Kanchan, and A.K. Panda Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response Biomaterials 28 2007 5344 5357
46. N. Csaba, M. Garcia-Fuentes, and M.J. Alonso Nanoparticles for nasal vaccination Adv. Drug Deliv. Rev. 61 2009 140 157
47. B.L. Farrugia, J.M. Whitelock, M. Jung, B. McGrath, R.L. O'Grady, S.J. McCarthy, and M.S. Lord The localisation of inflammatory cells and expression of associated proteoglycans in response to implanted chitosan Biomaterials 35 2014 1462 1477
48. X. Ferry, S. Brehin, R. Kamel, and Y. Landry G protein-dependent activation of mast cell by peptides and basic secretagogues Peptides 23 2002 1507 1515
49. M. Mousli, C. Bronner, J.L. Bueb, E. Tschirhart, J.P. Gies, and Y. Landry Activation of rat peritoneal mast cells by substance P and mastoparan J. Pharmacol. Exp. Therap. 250 1989 329 335
50. E. Passante, C. Ehrhardt, H. Sheridan, and N. Frankish RBL-2H3 cells are an imprecise model for mast cell mediator release Inflamm. Res.: Off. J. Eur. Histamine Res. Soc. 58 2009 611 618
51. T.-S. Vo, J.-A. Kim, D.-H. Ngo, C.-S. Kong, and S.-K. Kim Protective effect of chitosan oligosaccharides against FcRI-mediated RBL-2H3 mast cell activation Process Biochem. 47 2012 327 330
52. K. Tahara, S. Tadokoro, H. Yamamoto, Y. Kawashima, and N. Hirashima The suppression of IgE-mediated histamine release from mast cells following exocytic exclusion of biodegradable polymeric nanoparticles Biomaterials 33 2012 343 351
53. A. Buku Mast cell degranulating (MCD) peptide: a prototypic peptide in allergy and inflammation Peptides 20 1999 415 420
54. B. Slutter, S.M. Bal, I. Que, E. Kaijzel, C. Lowik, J. Bouwstra, and W. Jiskoot Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles? Mol. Pharm. 7 2010 2207 2215
55. U. Anand, T. Feridooni, and R.U. Agu Novel mucoadhesive polymers for nasal drug delivery A.D. Sezer, Recent Advances in Novel Drug Carrier Systems 2012 InTech < http://www.intechopen.com/books/recent-advances-in-novel-drug-carrier-systems/novel-mucoadhesive-polymers-for-nasal-drug-delivery >
56. W.M. Gwinn, B.T. Johnson, S.M. Kirwan, A.E. Sobel, S.N. Abraham, M.D. Gunn, and H.F. Staats A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen Vaccine 31 2013 1480 1489
57. R.J. Soane, M. Hinchcliffe, S.S. Davis, and L. Illum Clearance characteristics of chitosan based formulations in the sheep nasal cavity Int. J. Pharm. 217 2001 183 191
58. R.J. Soane, M. Frier, A.C. Perkins, N.S. Jones, S.S. Davis, and L. Illum Evaluation of the clearance characteristics of bioadhesive systems in humans Int. J. Pharm. 178 1999 55 65
59. E. Deat-Laine, V. Hoffart, G. Garrait, J.F. Jarrige, J.M. Cardot, M. Subirade, and E. Beyssac Efficacy of mucoadhesive hydrogel microparticles of whey protein and alginate for oral insulin delivery Pharm. Res. 30 2013 721 734
60. D. Tahtat, M. Mahlous, S. Benamer, A.N. Khodja, H. Oussedik-Oumehdi, and F. Laraba-Djebari Oral delivery of insulin from alginate/chitosan crosslinked by glutaraldehyde Int. J. Biol. Macromol. 58 2013 160 168
61. J.D. Smart The basics and underlying mechanisms of mucoadhesion Adv. Drug Deliv. Rev. 57 2005 1556 1568
62. D. Pawar, S. Mangal, R. Goswami, and K.S. Jaganathan Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity Eur. J. Pharm. Biopharm. 83 2013 550 559
63. T. Nochi, Y. Yuki, H. Takahashi, S. Sawada, M. Mejima, T. Kohda, N. Harada, I.G. Kong, A. Sato, N. Kataoka, D. Tokuhara, S. Kurokawa, Y. Takahashi, H. Tsukada, S. Kozaki, K. Akiyoshi, and H. Kiyono Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines Nat. Mater. 9 2010 572 578
64. Guideline on Adjuvants in Vaccines for Human Use (EMEA/CHMP/VEG/134716/2004), in: European Medicines Agency (EMA), London, 2005.
65. J.D. Watkins, A.M. Sholukh, M.M. Mukhtar, N.B. Siddappa, S.K. Lakhashe, M. Kim, E.L. Reinherz, S. Gupta, D.N. Forthal, Q.J. Sattentau, F. Villinger, D. Corti, and R.M. Ruprecht Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission AIDS 27 2013 F13 F20
66. S.E. Blutt, A.D. Miller, S.L. Salmon, D.W. Metzger, and M.E. Conner IgA is important for clearance and critical for protection from rotavirus infection Mucosal Immunol. 5 2012 712 719
67. A. Mori, E. Oleszycka, F.A. Sharp, M. Coleman, Y. Ozasa, M. Singh, D.T. O'Hagan, L. Tajber, O.I. Corrigan, E.A. McNeela, and E.C. Lavelle The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses Eur. J. Immunol. 42 2012 2709 2719
68. S.A. Khader, S.L. Gaffen, and J.K. Kolls Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa Mucosal Immunol. 2 2009 403 411
69. S.K. Datta, M. Sabet, K.P. Nguyen, P.A. Valdez, J.M. Gonzalez-Navajas, S. Islam, I. Mihajlov, J. Fierer, P.A. Insel, N.J. Webster, D.G. Guiney, and E. Raz Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax Proc. Natl. Acad. Sci. USA 107 2010 10638 10643